Summarized by Masters of Longevity from Longevity Technology.
A short news piece about early human trial results for a novel metabolic drug, inviting readers to learn what the study and next steps promise.
Key Takeaways
- An investigator-initiated, open-label single-arm study in 13 overweight or obese subjects tested the oral GRK2-biased β2-adrenergic modulator ATR-258 over eight weeks.
- ATR-258 was reported as well tolerated across three ascending dose levels in this study.
- Atrogi plans a Phase 2 trial in 2027 to seek clinical proof-of-concept for muscle-sparing weight loss and sarcopenia, and initial results will be presented at an international conference.
